Haemonetics (HAE) SEC filings

Haemonetics's latest annual report is a Form 10-K filed on May 20, 2026 for the period ended March 28, 2026. Its latest quarterly report, a Form 10-Q, was filed on November 5, 2026. Its latest current report, a Form 8-K, was filed on November 5, 2026 (2.02 Results of Operations and Financial Condition).

Key facts

Latest annual report
10-K, May 20, 2026
Latest quarterly report
10-Q, Nov 5, 2026
Latest 8-K
8-K, Nov 5, 2026
Filings, last 12 months
50
Insider forms, last 12 months
21Forms 3, 4 and 5
13D and 13G, last 12 months
7
SEC central index key
0000313143

Filings as listed by SEC EDGAR at (re-read at most hourly). Source: SEC EDGAR filings for CIK 0000313143. Every form links to its document on sec.gov. Older filings are in EDGAR's archive; the tables here cover its recent list (at least the last year).

Annual and quarterly reports

Haemonetics: annual and quarterly reports filed with the SEC
FormFiledPeriod endedDocument
10-QQuarterly report
10-QQuarterly report
10-KAnnual report
10-QQuarterly report
10-QQuarterly report
10-QQuarterly report
10-KAnnual report
10-QQuarterly report
10-QQuarterly report
10-QQuarterly report
10-KAnnual report
10-QQuarterly report
10-QQuarterly report
10-QQuarterly report
10-KAnnual report
10-QQuarterly report

The latest 16 of 55 in EDGAR's recent list. Amended reports are marked. The period is the fiscal year or quarter the report covers.

Current reports (8-K)

Haemonetics: current reports on Form 8-K and the items each reports
FormFiledEvent dateWhat it reports
8-K2.02 Results of Operations and Financial Condition9.01 Financial Statements and Exhibits
8-K7.01 Regulation FD Disclosure
8-K7.01 Regulation FD Disclosure
8-K2.02 Results of Operations and Financial Condition9.01 Financial Statements and Exhibits
8-K5.02 Departure or Election of Directors or Officers; Officer Compensation5.07 Submission of Matters to a Vote of Security Holders9.01 Financial Statements and Exhibits
8-K7.01 Regulation FD Disclosure9.01 Financial Statements and Exhibits
8-K2.02 Results of Operations and Financial Condition9.01 Financial Statements and Exhibits
8-K5.02 Departure or Election of Directors or Officers; Officer Compensation
8-K7.01 Regulation FD Disclosure
8-K7.01 Regulation FD Disclosure
8-K2.02 Results of Operations and Financial Condition9.01 Financial Statements and Exhibits
8-K8.01 Other Events9.01 Financial Statements and Exhibits
8-K2.02 Results of Operations and Financial Condition9.01 Financial Statements and Exhibits
8-K2.02 Results of Operations and Financial Condition9.01 Financial Statements and Exhibits
8-K5.07 Submission of Matters to a Vote of Security Holders
8-K2.02 Results of Operations and Financial Condition2.05 Costs Associated with Exit or Disposal Activities9.01 Financial Statements and Exhibits
8-K5.02 Departure or Election of Directors or Officers; Officer Compensation7.01 Regulation FD Disclosure9.01 Financial Statements and Exhibits
8-K2.02 Results of Operations and Financial Condition9.01 Financial Statements and Exhibits
8-K8.01 Other Events9.01 Financial Statements and Exhibits
8-K5.02 Departure or Election of Directors or Officers; Officer Compensation

The latest 20 of 155 in EDGAR's recent list. Item names are the SEC's own, from Form 8-K (a few long ones shortened). The event date is the date of the earliest event reported.

Insider forms (3, 4 and 5)

Haemonetics: insider forms 3, 4 and 5 filed per month over the last twelve months
MonthForms filed
Nov 20262
Oct 20260
Sep 20260
Aug 20260
Jul 20269
Jun 20262
May 20268
Apr 20260
Mar 20260
Feb 20260
Jan 20260
Dec 20250
Haemonetics: the latest insider forms
FormFiledTransaction date
4
4
4
4
4
4
4
4
4
4
3
4
4
4
4
4
4
4
4
4

The latest 20 of 629 in EDGAR's recent list. Each form is filed by the insider about their own holding; the trade details are inside the form on sec.gov. Counts include amendments. The current month is counted to date.

Ownership reports (Schedules 13D and 13G)

Haemonetics: Schedule 13D and 13G beneficial ownership reports
FormFiledEvent date
Schedule 13G (amended)—
Schedule 13G (amended)—
Schedule 13G—
Schedule 13G—
Schedule 13G (amended)—
Schedule 13G—
Schedule 13G—
Schedule 13G (amended)—
Schedule 13G (amended)—
Schedule 13G (amended)—
Schedule 13G (amended)—
Schedule 13G—
Schedule 13G (amended)—
Schedule 13G (amended)—
Schedule 13G (amended)—
Schedule 13G (amended)—
Schedule 13G (amended)—
Schedule 13G (amended)—
Schedule 13G (amended)—
Schedule 13G (amended)—

The latest 20 of 75 in EDGAR's recent list. Filed by the holder, not the company. EDGAR's list names the form and date; who filed it is in the document.

Proxy statements

Haemonetics: proxy statements and proxy materials
FormFiledMeeting or periodDocument
DEFA14A—
DEF 14ADefinitive proxy statement
DEFA14A—
DEF 14ADefinitive proxy statement
DEFA14A—
DEF 14ADefinitive proxy statement
DEFA14A—
DEF 14A—Definitive proxy statement
DEFA14A—
DEF 14ADefinitive proxy statement
DEFA14A—
DEF 14ADefinitive proxy statement
DEFA14A—
DEFA14A—
DEF 14ADefinitive proxy statement
DEFA14A—
DEF 14ADefinitive proxy statement
PRE 14APreliminary proxy statement
DEFA14A—
DEFA14A—HAEMONETICS CORPORATION - DEFA14A

The latest 20 of 28 in EDGAR's recent list.

Everything else (58 filings: registrations, prospectuses, Rule 144 notices, correspondence and more)
Haemonetics: other SEC filings
FormFiledPeriodDocument
144—Notice of proposed sale
S-8—Registration statement for employee plans
ARS
SD—Specialized disclosure report
144—Notice of proposed sale
144—Notice of proposed sale
ARS
144—Notice of proposed sale
144—Notice of proposed sale
SD—Specialized disclosure report
144—Notice of proposed sale
144—Notice of proposed sale
144—Notice of proposed sale
144—Notice of proposed sale
144—Notice of proposed sale
ARS
144—Notice of proposed sale
144—Notice of proposed sale
SD—Specialized disclosure report
144—Notice of proposed sale
144—Notice of proposed sale
144—Notice of proposed sale
144—Notice of proposed sale
144—Notice of proposed sale
144—Notice of proposed sale
144—Notice of proposed sale
144—Notice of proposed sale
144—Notice of proposed sale
144—Notice of proposed sale
144—Notice of proposed sale
144—Notice of proposed sale
S-8—Registration statement for employee plans
144—Notice of proposed sale
ARS
144—Notice of proposed sale
SD—Specialized disclosure report
144—Notice of proposed sale
SD—Specialized disclosure report
SD—Specialized disclosure report
SD—Specialized disclosure report
EFFECT—
POS AM—
S-8—Registration statement for employee plans
SD—Specialized disclosure report
CT ORDER—
SD—HAEMONETICS CORPORATION - FORM SD
S-8—Registration statement for employee plans
CT ORDER—
NO ACTAUTO-GENERATED PAPER DOCUMENT
SD—FORM SD
UPLOAD—
CORRESP—
UPLOAD—
SD—SPECIALIZED DISCLOSURE REPORT
SD—SD 2015
S-8—Registration statement for employee plans
SD—Specialized disclosure report
UPLOAD—

What the forms are

Form 3 — Initial statement of beneficial ownership
An insider's first statement of holdings in the company's equity securities. Insiders are officers, directors and holders of more than 10 percent of a class of its registered equity securities.
Form 4 — Statement of changes in beneficial ownership
An insider's transactions in the company's equity securities, disclosed within two business days of the transaction.
Form 5 — Annual statement of beneficial ownership
An insider's annual statement of holdings in the company's equity securities.
Form 144 — Notice of proposed sale
In the SEC's Forms Index: notice of proposed sale of securities pursuant to Rule 144.
Form 10-K — Annual report
Audited annual financial statements, a discussion of material risk factors, and management's discussion and analysis of the results for the prior fiscal year.
Form 10-Q — Quarterly report
Unaudited quarterly financial statements, updates on material risks, and management's discussion and analysis of the results for the prior fiscal quarter.
Form 8-K — Current report
Discloses material events or information the company chooses or is required to make public before its next scheduled quarterly or annual report. Each report lists the items it covers.
Schedule 13G — Schedule 13G beneficial ownership report
Filed when a party acquires more than five percent of a class of the company's registered voting securities as a passive investment.
Form DEF 14A — Definitive proxy statement
The final proxy statement sent to shareholders for a shareholder meeting: the matters to be voted on, and typically executive and board compensation and who owns more than five percent.
Form PRE 14A — Preliminary proxy statement
A preliminary proxy statement subject to review by the SEC staff.
Form S-8 — Registration statement for employee plans
In the SEC's Forms Index: registration statement under the Securities Act of 1933 for securities to be offered to employees under certain plans.
Form SD — Specialized disclosure report
In the SEC's Forms Index: Specialized Disclosure Report.

From the SEC's own descriptions: SEC, Using EDGAR to Research Investments; SEC, Forms Index; SEC, Form 8-K and its items (PDF).

Questions and answers

Where is Haemonetics's latest annual report (10-K)?

Haemonetics filed its latest Form 10-K with the SEC on May 20, 2026 for the period ended March 28, 2026. The table of annual and quarterly reports on this page links to the document on sec.gov.

When did Haemonetics file its latest 10-Q?

On November 5, 2026 for the period ended September 26, 2026. A Form 10-Q holds unaudited quarterly financial statements and management's discussion of the quarter.

What has Haemonetics reported on Form 8-K recently?

Its latest 8-K was filed on November 5, 2026 (2.02 Results of Operations and Financial Condition). In the last twelve months the items it reported most often were: 7.01 Regulation FD Disclosure (5 reports); 2.02 Results of Operations and Financial Condition (4 reports); 5.02 Departure or Election of Directors or Officers; Officer Compensation (2 reports). An 8-K discloses material events before the next quarterly or annual report.

How many insider filings (Forms 3, 4 and 5) were there for HAE in the last year?

21 insider forms in the twelve months to November 18, 2026, the latest a Form 4 filed on November 13, 2026. Officers, directors and holders of more than 10 percent of a class of the company's registered equity securities must disclose their holdings and transactions; a Form 4 is due within two business days of a trade.

Has anyone reported owning more than 5% of Haemonetics?

EDGAR lists 7 Schedule 13D or 13G filings about Haemonetics in the last twelve months, the latest on August 12, 2026. These are filed by a party that acquires more than five percent of a class of the company's voting securities; 13G is for passive investors.

Cite this page

Funkfolio, “Haemonetics (HAE) SEC filings: latest 10-K, 10-Q and 8-K”, data as of 18 November 2026. https://funkfolio.com/stock/HAE/filings

Underlying data: SEC EDGAR submissions (data.sec.gov).